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Summary.-The concentration of circulating ferritin was measured in 250 normal
adult women and 229 women presenting with early breast cancer. Ferritin
concentrations are higher in cancer patients than in normal women. Patients with
an initial circulating ferritin concentration above 200 ,ug/l have a higher tumour
recurrence rate during the subsequent 4 years.
FERRITIN is the major iron storage
protein in tissues and most of the studies
reported since its isolation 40 years ago
have related to iron metabolism (Harrison
et al., 1974). More recently, small
amounts have been detected in plasma,
and in otherwise healthy subjects the
concentration of the circulating protein
is related to the amount of reticuloendo-
thelial (RE) storage iron in the body
(Jacobs and Worwood, 1975). Elevated
levels have been reported in leukaemia
and Hodgkin's disease (Jones et al., 1973)
and, in the case ofacuteleukaemia, this is
associated with increased synthesis and
high concentrations in the malignant
cells (Worwood et al., 1974; White et al.,
1974). The analysis of normal tissue
ferritin by isoelectric focusing has re-
vealed considerable heterogeneity
(Drysdale, 1974; Powell et al., 1975).
Alpert, Coston and Drysdale (1973) found
human hepatoma tissue to contain an
acidic ferritin also present in early foetal
liver but not in mature liver. Marcus
and Zinberg (1974) showed that ferritin
isolated from breast and pancreatic
tumour tissue contained acidic isoferritins
not found in adult liver, while Drysdale
and Singer (1974) demonstrated acidic
isoferritins in HeLa cells and in placenta.
Both groups of workers suggested the
term " carcinofetal " isofoerritin and dis-
cussed the possibility of developing sero-
logical tests for cancer based on the
characteristics ofthis protein.
The suggestion by Marcus and Zinberg
(1974) that breast cancer tissue might
produce its own characteristic ferritin,
together with their initial report (Marcus
and Zinberg, 1975a) of increased serum
ferritin concentrations in patients with
the disease, stimulated the present study.
We have estimated circulating ferritin
concentration in 229 women presenting
with early breast cancer and compared
the data with that from 250 normal
women. The relationship between circu-
lating ferritin and recurrence of the
tumour has also been examined.
METHODS
Serum samples were collected from 153
apparently healthy, non-anaemic women
over the age of 16 years, living in the Cardiff
area. Plasma samples were obtained from
97 normal women aged over 18 years living
in Guernsey and from 229 women presenting
for the first time with untreated breast
cancer (Stages I and II). All samples
were coded and ferritin estimations were
carried out by the method of Jones and
Worwood (1975). Only when the ferritinFERRITIN CONCENTRATION IN BREAST CANCER
levels had been measured was the code
broken.
The patients with breast cancer were
followed for up to 5 years from the time of
presentation and the interval to recurrence
was noted. The results of initial serum
ferritin estimations were evaluated by
standard statistical methods (Siegel, 1956)
and the relationship between initial ferritin
concentration and recurrence of the cancer
was analysed using both the method of
Watson (1967) and the log rank test (Peto,
1972).
RESULTS
There was no significant difference,
either in mean values or in distribution,
between the normal samples collected in
Cardiffand Guernsey. These groups were
therefore amalgamated. The total of
250 normal adult women had a mean
serum ferritin concentration of56*6±56-9
(s.d.) ,tg/l. The women with breast cancer
had a mean serum ferritin concentration
of 96-9jtg/l with s.d. 96-8 ,ug/l. Both
groups show a marked skew distribution
of values (Fig. 1) and the apparent excess
of higher values in the cancer group is
a
"a
E
z
50
40
30
20
10
significant usingthe Kolmogorov-Smirnov
test(D= 0215,P<0-0005). Transforma-
tion of the data reveals an approximately
log-normal distribution in both cases.
The combined group of controls had a
mean log ferritin value of 1F59 with an
s.d. of 0.10 compared to 1-79 with an
s.d. of 0 12 for the cancer group and the
difference between the means is highly
significant (t = 5 30, P<0 001).
A serum ferritin concentration greater
than 120,tg/l is found in only 5% of
normal women, but occurs in approxi-
mately 25% of patients with breast
cancer (Fig. 1). In order to determine
whether these abnormally high values
were related to prognosis, the recurrence
rates were calculated for patients with
plasma ferritin concentrations above and
below 120,ug/l. The results are shown in
Fig. 2, and it can be seen that the re-
currence rates for these groups were
almost identical. Finally, the recurrence
rate was calculated forthe 10% ofpatients
with the highest concentrations of serum
ferritin (201 ,ug/l) andthis wassignificantly
greater than that for women with lower
levels offerritin (P<004).
BREAST CANCER
NORMAL WOMEN
Serum frritin concentration pgW/
FIG. 1.-Circulating ferritin concentration in 250 normal women and 229 patients with early breast cancer.
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FIG. 2. Probability of non-recurrence in breast cancer patients comparing 3 groups dlistinguished by their
initial plasma ferritin concentration on first presentation.
The majority of recurrences occurred
within 3 years, and at the time of this
study none had been seen later than 3
years 6 months. In view of the im-
portance of an increased recurrence rate
in women with an initial high serum
ferritin, the data was also analysed by the
log rank test. This showed no significant
difference in the rate of recurrence
between patients with an initial serum
ferritin concentration above 200 /tg/l com-
pared with those having lower values
(X2 3.37, 0.10>P>0 05). Similarly
the recurrence rate is no different in those
patients with an initial ferritin less than
20pig/l compared with those above 20,g/l
when the log rank test is used.
DISCUSSION
The serum ferritin levels in normal
women reported here agree with those
found previously by ourselves (Jacobs
et al., 1972) and other workers (Cook,
Lipschitz and Miles, 1974; Halliday,
Gera and Powell, 1975; Marcus and
Zinberg, 1975b) using alternative assay
techniques. Marcus and Zinberg (1975b)
have reported raised serum ferritin levels
in 14 out of 38 women with preoperative
breast cancer and in 65 out of 97 women
with recurrent or metastatic breast cancer.
They found a mean serum ferritin of
34/ag/l in 117 normal women and 199 ,tg/l
in those with untreated breast cancer.
The difference between normal women
and those with early cancer in the present
series is not quite so great as this, possibly
due to the rather low normal values
found by Marcus and Zinberg. They do
not give details of their preoperative
cases. However, the present data con-
firm their observation ofhigher circulating
ferritin levels in patients with breast
cancer.
There are many possible reasons for
high concentrations of circulating ferritin.
Levels comparable to those found in the
present group of patients could be due to
increasediron stores, inflammatory disease,
liver damage or malignancy (Jacobs and
Worwood, 1975). The reasons for high
serum ferritin levels in patients with
malignant disease is still far from clear,
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though it is tempting to consider it as the
expression of a tumour-produced protein.
The only direct evidence for increased
ferritin synthesis in human malignant
tissue is that of White et al. (1974) in the
case of acute myeloblastic leukaemia.
Ferritin has been identified in Hodgkin's
tumours (Bieber and Bieber, 1973; Eshhar,
Order and Katz, 1974) and in breast
tumour (Marcus and Zinberg, 1974) but
this is not altogether surprising, as the
capacity to synthesize this protein has
been found in every mammalian tissue
studied (Harrison et al., 1974). Jones
et al. (1973) pointed out that neoplasia
is commonly associated with an ab-
normality of iron metabolism which
manifests itself by a low serum iron
concentration, an increase in RE iron
and the anaemia of chronic disease (Cart-
wright and Lee, 1971). The majority
of patients with Hodgkin's disease show
this phenomenon and although it is most
marked in those with advanced disease
it is present in all stages (Beamish et al.,
1972). The abnormality is thought to
reflect a secondary metabolic disorder in
RE cells which accumulate ferritin. and
release iron only ineffectively to the
plasma transferrin pool. In patients with
rheumatoid arthritis who display a similar
phenomenon, high serum ferritin concen-
trations are associated with a reduction
of serum iron and transferrin saturation.
Jones et al. (1973) considered the high
serum ferritin in Hodgkin's disease to be a
reflection of this RE block of iron release
and the data ofJacobs et al. (1976) support
this concept. It seems likely that a
similar state exists in patients with
breast cancer and other malignant states.
While Drysdale and Singer (1974) and
Marcus and Zinberg (1974) have suggested
that tumour cells may produce an acidic
" carcinofoetal " isoferritin characteristic
of the malignant state, this concept
appears to be an over-simplification.
There is considerable heterogeneity of the
isoferritin pattern found in tumours.
This has been demonstrated both in
induced rat hepatomas (Urushizaki et al.,
1973) and in human myeloblastic
leukaemia (Wagstaff et al., 1976). Marcus
and Zinberg (1974) reporting on mammary
and pancreatic carcinomas say that the
relative proportions of normal and acidic
ferritins vary. It is also clear that
" acidic " isoferritins are not confined to
malignant tissue, and are present in
normal human myocardium and erythro-
cytes. Isoelectric focusing of purified
human serum ferritin from patients with
iron overload shows the presence of a
major alkaline band with a pl about
5 7, which does not correspond to any
known tissue ferritin and presumably
results from inodification of the molecule
during a secretory process (Worwood
et al., 1976). There are other serum
bands corresponding to the usual tissue
ferritins and including acid components
(pl 5-0-5-1) similar to those found in
HeLa cells, breast cancer, placenta and
normal cardiac tissue.
Marcus and Zinberg (1975b) suggest
that, despite the uncertainties regarding
the origin and nature of serum ferritin,
its estimation may be of empirical value
in cancer immunodiagnosis. While there
are undoubted immunological differences
between the acidic and alkaline isoferritins
(Marcus and Zinberg, 1975b; Jacobs,
1976; and Worwood, Jones and Jacobs,
1976) there is not yet any evidence of a
difference between normal and malignant
isoferritins which could form the basis of a
specific assay.
The present evidence suggests that,
while patients with early breast cancer
have serum ferritin concentrations some-
what higher than normal, this could
result from the non-specific effect of
malignancy on RE iron metabolism.
The degree of increase is not comparable
to that in acute leukaemia, where levels
25 times normal are found (Parry, Wor-
wood and Jacobs, 1975). Whatever the
mechanism of high circulating ferritin
levels in cancer patients, the data point
to a difference in tumour recurrence rate
in the high ferritin group.
Tormey et al (1975) have shown that,
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whilst an abnormality inthe concentration
of CEA, HCG or dimethylguanosine
occurred in 30-45% ofpatients with early
breast cancer, 67% of these women had
an abnormal value in at least one of these
substances, and they go on to make the
point that accurate prognosis might be
obtained by measurement of multiple
tumour markers. It seems possible from
the present report that women with
serum ferritin levels greater than 200 ,tg/l
have a greater recurrence rate than
patients with lower ferritin values.
Although these high concentrations are
only found in 10% of breast cancer
subjects, such a marker might prove
useful, in combination with other tests,
in predicting the clinical course of the
disease.
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